L'ASSOCIATION ENTRE L'HALOPERIDOL ET L'ORPHENADRINE DANS LA THERAPIE DE LA SCHIZOPHRENIE: UNE ETUDE CLINIQUE ET PHARMACOCINETIQUE

A. C. Altamura, M. Buccio, G. Colombo, A. Terzi, C. L. Cazzullo

Research output: Contribution to journalArticle

Abstract

The use of anti-cholinergic drugs for counteracting neuroleptic induced extrapyramidal side-effects (EPS) is controversial. A possible increase in anticholinergic symptoms and a pharmacokinetic interaction are reported in literature. In order to determine these points, 22 schizophrenic patients were studied. Haloperidol (HL) was administered for 3 weeks and Orphenadrine (ORD) only in the second week of treatment. ORD reduced significantly EPS and its withdrawal led to a marked deterioration of EPS and the psychopathological picture. There was an increase in HL plasma levels after starting ORD, and ORD plasma levels were positively related to EPS amelioration. Finally, prolactin seemed to be higher in those patients with EPS, particularly after ORD withdrawal.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalEncephale
Volume12
Issue number1
Publication statusPublished - 1986

Fingerprint

Orphenadrine
Haloperidol
Cholinergic Antagonists
Prolactin
Cholinergic Agents
Antipsychotic Agents
Pharmacokinetics
Étude
Plasma

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

L'ASSOCIATION ENTRE L'HALOPERIDOL ET L'ORPHENADRINE DANS LA THERAPIE DE LA SCHIZOPHRENIE : UNE ETUDE CLINIQUE ET PHARMACOCINETIQUE. / Altamura, A. C.; Buccio, M.; Colombo, G.; Terzi, A.; Cazzullo, C. L.

In: Encephale, Vol. 12, No. 1, 1986, p. 31-36.

Research output: Contribution to journalArticle

@article{b5ac19f3a9984931bebca4e01cca4983,
title = "L'ASSOCIATION ENTRE L'HALOPERIDOL ET L'ORPHENADRINE DANS LA THERAPIE DE LA SCHIZOPHRENIE: UNE ETUDE CLINIQUE ET PHARMACOCINETIQUE",
abstract = "The use of anti-cholinergic drugs for counteracting neuroleptic induced extrapyramidal side-effects (EPS) is controversial. A possible increase in anticholinergic symptoms and a pharmacokinetic interaction are reported in literature. In order to determine these points, 22 schizophrenic patients were studied. Haloperidol (HL) was administered for 3 weeks and Orphenadrine (ORD) only in the second week of treatment. ORD reduced significantly EPS and its withdrawal led to a marked deterioration of EPS and the psychopathological picture. There was an increase in HL plasma levels after starting ORD, and ORD plasma levels were positively related to EPS amelioration. Finally, prolactin seemed to be higher in those patients with EPS, particularly after ORD withdrawal.",
author = "Altamura, {A. C.} and M. Buccio and G. Colombo and A. Terzi and Cazzullo, {C. L.}",
year = "1986",
language = "English",
volume = "12",
pages = "31--36",
journal = "L'Encephale",
issn = "0013-7006",
publisher = "Elsevier Masson",
number = "1",

}

TY - JOUR

T1 - L'ASSOCIATION ENTRE L'HALOPERIDOL ET L'ORPHENADRINE DANS LA THERAPIE DE LA SCHIZOPHRENIE

T2 - UNE ETUDE CLINIQUE ET PHARMACOCINETIQUE

AU - Altamura, A. C.

AU - Buccio, M.

AU - Colombo, G.

AU - Terzi, A.

AU - Cazzullo, C. L.

PY - 1986

Y1 - 1986

N2 - The use of anti-cholinergic drugs for counteracting neuroleptic induced extrapyramidal side-effects (EPS) is controversial. A possible increase in anticholinergic symptoms and a pharmacokinetic interaction are reported in literature. In order to determine these points, 22 schizophrenic patients were studied. Haloperidol (HL) was administered for 3 weeks and Orphenadrine (ORD) only in the second week of treatment. ORD reduced significantly EPS and its withdrawal led to a marked deterioration of EPS and the psychopathological picture. There was an increase in HL plasma levels after starting ORD, and ORD plasma levels were positively related to EPS amelioration. Finally, prolactin seemed to be higher in those patients with EPS, particularly after ORD withdrawal.

AB - The use of anti-cholinergic drugs for counteracting neuroleptic induced extrapyramidal side-effects (EPS) is controversial. A possible increase in anticholinergic symptoms and a pharmacokinetic interaction are reported in literature. In order to determine these points, 22 schizophrenic patients were studied. Haloperidol (HL) was administered for 3 weeks and Orphenadrine (ORD) only in the second week of treatment. ORD reduced significantly EPS and its withdrawal led to a marked deterioration of EPS and the psychopathological picture. There was an increase in HL plasma levels after starting ORD, and ORD plasma levels were positively related to EPS amelioration. Finally, prolactin seemed to be higher in those patients with EPS, particularly after ORD withdrawal.

UR - http://www.scopus.com/inward/record.url?scp=0022596531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022596531&partnerID=8YFLogxK

M3 - Article

C2 - 3698889

AN - SCOPUS:0022596531

VL - 12

SP - 31

EP - 36

JO - L'Encephale

JF - L'Encephale

SN - 0013-7006

IS - 1

ER -